Effects of ibopamine in combination with furosemide on renal function in patients with chronic congestive heart failure. 1988

E Vitolo, and G Segalini, and L Carini, and D Castini, and A Moreo, and C Mazzola, and S Segagni, and G Villa, and A Salvadeo
Bassini Institute of Biomedical Sciences, University of Milan, Italy.

The effects of ibopamine and furosemide on renal function given alone and in combination at single doses were studied in 6 men and 6 women aged 45 to 73 years with chronic congestive heart failure of NYHA class II. After 3 days of dietary stabilization, the patients received either ibopamine 200 mg, furosemide 40 mg, or furosemide 40 mg plus ibopamine 200 mg with 2-day washout between treatments, according to a double-blind, balanced three-way crossover design using all possible treatment sequences. On each treatment day urine collections were performed at 2-hourly intervals from 2 h before to 6 h after dosing, and urine volume and Na+, K+, Cl-, and creatinine concentrations were measured for every period. The patients received a standardized breakfast 3 h before treatment and then were allowed 250 ml tap water to drink before starting each urine collection period. Venous blood samples were taken before breakfast and midway between each urine collection period for analysis of serum Na+, K+, Cl-, creatinine, and glucose. Heart rate, blood pressure, and physical signs were recorded 2, 1 h, immediately before, and then 0.5, 1, 2, 3, 4, 5, and 6 h after treatment. At the same times the patients were asked for any symptoms. The time course of the diuretic effect of furosemide 40 mg was consistent with the data reported by other authors.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007677 Kidney Function Tests Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine. Function Test, Kidney,Function Tests, Kidney,Kidney Function Test,Test, Kidney Function,Tests, Kidney Function
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002712 Chlorides Inorganic compounds derived from hydrochloric acid that contain the Cl- ion. Chloride,Chloride Ion Level,Ion Level, Chloride,Level, Chloride Ion
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D003846 Deoxyepinephrine Sympathomimetic, vasoconstrictor agent. Deoxyadrenaline,Desoxyadrenaline,Methyldopamine,Desoxyepinephrine,Epinine
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

E Vitolo, and G Segalini, and L Carini, and D Castini, and A Moreo, and C Mazzola, and S Segagni, and G Villa, and A Salvadeo
September 1990, British journal of clinical pharmacology,
E Vitolo, and G Segalini, and L Carini, and D Castini, and A Moreo, and C Mazzola, and S Segagni, and G Villa, and A Salvadeo
February 1993, European heart journal,
E Vitolo, and G Segalini, and L Carini, and D Castini, and A Moreo, and C Mazzola, and S Segagni, and G Villa, and A Salvadeo
July 1995, American journal of therapeutics,
E Vitolo, and G Segalini, and L Carini, and D Castini, and A Moreo, and C Mazzola, and S Segagni, and G Villa, and A Salvadeo
February 1990, Zeitschrift fur Kardiologie,
E Vitolo, and G Segalini, and L Carini, and D Castini, and A Moreo, and C Mazzola, and S Segagni, and G Villa, and A Salvadeo
January 1990, Cardiology,
E Vitolo, and G Segalini, and L Carini, and D Castini, and A Moreo, and C Mazzola, and S Segagni, and G Villa, and A Salvadeo
May 1991, The American journal of medicine,
E Vitolo, and G Segalini, and L Carini, and D Castini, and A Moreo, and C Mazzola, and S Segagni, and G Villa, and A Salvadeo
December 2011, Journal of cardiac failure,
E Vitolo, and G Segalini, and L Carini, and D Castini, and A Moreo, and C Mazzola, and S Segagni, and G Villa, and A Salvadeo
January 1989, Journal of cardiovascular pharmacology,
E Vitolo, and G Segalini, and L Carini, and D Castini, and A Moreo, and C Mazzola, and S Segagni, and G Villa, and A Salvadeo
January 1982, Journal of cardiovascular pharmacology,
E Vitolo, and G Segalini, and L Carini, and D Castini, and A Moreo, and C Mazzola, and S Segagni, and G Villa, and A Salvadeo
May 1985, British journal of clinical pharmacology,
Copied contents to your clipboard!